Exelixis Inc (EXEL)
22.33
+1.02 +4.79%
NASDAQ
Mar 5, 20:00
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 987.54M |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | 0.35 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | 111.78M |
Profitability | |
Gross Profit Margin (Quarterly) | 96.65% |
Profit Margin (Quarterly) | 10.51% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0.00% |
Price and Valuation | |
Market Cap | 6.967B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 7.138 |
PE Ratio | 63.80 |
Price to Book Value | 3.708 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.00 |
Free Cash Flow (Quarterly) | 19.00M |
Return on Equity | Upgrade |
View All EXEL News
News
-
WireHeadlineTime (ET)
-
SA Breaking News02/26 06:59
-
Yahoo02/26 06:30
-
Yahoo02/25 16:05
-
SA Breaking News02/25 08:36
-
Yahoo02/25 08:00
-
Yahoo02/19 16:07
-
Yahoo02/17 06:06
-
MT Newswires02/16 10:30
-
Yahoo02/16 09:01
-
SA Breaking News02/16 08:22
-
SA Breaking News02/16 06:58
-
Business Wire02/13 13:00
-
Yahoo02/12 17:15
-
Yahoo02/11 15:00
-
Yahoo02/11 07:00
-
Yahoo02/10 17:55
-
MT Newswires02/10 16:42
-
SA Breaking News02/10 16:41
-
Yahoo02/10 16:40
-
MT Newswires02/10 16:07
View All Events
Events
Date | Type | Description |
---|---|---|
05/05/2021 | Earnings | Exelixis Inc First Quarter Earnings Results for 2021 |
05/05/2021 | Misc | Exelixis Inc First Quarter Earnings Conference Call for 2021 |
02/11/2021 | Misc | Exelixis Inc Annual Report for 2020 |
02/10/2021 | Earnings | Exelixis Inc Fourth Quarter Earnings Result for 2020 |
02/10/2021 17:00 EST | Misc | Exelixis Inc Fourth Quarter Earnings Conference Call for 2020 |
11/05/2020 | Earnings | Exelixis Inc Third Quarter Earnings Result for 2020 |
11/05/2020 17:00 EST | Misc | Exelixis Inc Third Quarter Earnings Conference Call for 2020 |
08/06/2020 17:30 EDT | Misc | Exelixis Inc Second Quarter Earnings Conference Call for 2020 |
08/06/2020 | Earnings | Exelixis Inc Second Quarter Earnings Result for 2020 |
05/20/2020 10:00 PDT | Misc | Exelixis Inc Annual General Meeting for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.exelixis.com
- Investor Relations URL: http://www.exelixis.com/investors-media
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: May. 05, 2021
- Last Earnings Release: Feb. 10, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 22.33 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Top Fund Holders
Symbol | Name | Weighting |
---|---|---|
IDNA | iShares Genomics Immnlgy & Hlthcr ETF | 4.66% |
VALLX | Value Line Larger Companies Focused Inv | 3.80% |
FBT | First Trust NYSE Arca Biotech ETF | 3.41% |
VLIIX | Value Line Capital Appreciation Instl | 3.34% |
FTZIX | Fuller & Thaler Behvrll Uncnstd Eq Instl | 3.07% |
CAMSX | Cambiar Small Cap Inv | 2.16% |
FIJYX | Fidelity Advisor® Biotechnology Z | 1.64% |
HQL | Tekla Life Sciences Investors | 1.52% |
FBIOX | Fidelity® Select Biotechnology | 1.05% |
XBI | SPDR® S&P Biotech ETF | 1.01% |
HQH | Tekla Healthcare Investors | 0.99% |
LABU | Direxion Daily S&P Biotech Bull 3X ETF | 0.86% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- EXEL Tweets Stocktwits
Advertisement